Image source: Getty Images.
The past 12 months have been tough on healthcare stocks across the sector, but robotic surgery upstart TransEnterix (NYSEMKT: TRXC) has taken a more severe beating than most. The stock rose sharply in anticipation of FDA clearance for its SurgiBot system, then crashed when the regulator deemed it “not substantially equivalent” to existing devices in April.